Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive

Published:2011-06 Issue:3 Volume:5 Page:413-424
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Santarpia Mariacarmela,Altavilla Giuseppe,Salazar Maria F,Magri Ignacio,Pettineo Giuseppe,Benecchi Sara,Rosell Rafael

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1586/ers.11.27

Reference98 articles.

1. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

2. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

3. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

4. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

5. Targeted therapies for non-small cell lung cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Non‐invasive Molecular Biomarkers for Early Cancer Detection;Genomic and Epigenomic Biomarkers of Toxicology and Disease;2022-04-27

2. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis;International Journal of Oncology;2018-11-06

3. EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP);Targeted Oncology;2018-10

4. Liquid biopsy for lung cancer early detection;Journal of Thoracic Disease;2018-04

5. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy;Drug Design, Development and Therapy;2017-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3